CPMC.

Methods	Patients were stratified according to number of days lapsed since the onset of SAH and the postoperative clinical condition (assessed by means of the H&H grading system). Randomisation was done postoperatively by means of an on‐site computer system to either hypervolemic treatment or normovolemic treatment. Clinical outcome and the occurrence of symptomatic vasospasm were assessed in an unblinded fashion. Clinical outcome was assessed according to an intention‐to‐treat analysis.
Participants	Setting: 1 centre (Columbia ‐ Presbyterian Medical Centre). Rx: 42 patients; control: 42 patients. Eligible were patients undergoing aneurysmal clipping on or before the sixth day after onset of SAH. Further inclusion criteria were: (1) H&H grade I through IV after operation; (2) age between 18 and 80 years; (3) no symptomatic vasospasm immediately after operation. Exclusion criteria were: (1) congestive heart failure; (2) pregnancy; and (3) renal insufficiency.
Interventions	All patients received a baseline crystalloid infusion of 80 ml/h 5% dextrose and 0.9% saline. Patients assigned to the hypervolaemia treatment received additional 5% albumin solution (250 ml/2hrs) if PADP fell below 14 mmHg or CVP fell below 8 mmHg. Patients in the control group received similar albumin infusions if PAD fell below 7 mmHg or CVP below 5 mmHg. In both groups, patients who developed secondary ischaemia were switched to a hypertensive‐hypervolemic protocol.
Outcomes	Clinical outcome was assessed according to the Glasgow Outcome Scale at 14 days and 3 months after SAH. Symptomatic vasospasm was defined as a focal neurological deficit or deterioration in the level of consciousness, with either confirmation of infarction in CT scans or exclusion of other possible causes. Other outcome measurements were: cerebral blood volume; cerebral blood flow; blood pressure and volume status.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate